The Effectiveness of Two Osteoporosis Drugs on Prosthetic Bone Mineral Density (BMD) Loss After Total Hip Arthroplasty(THA)
This trial is active, not recruiting.
|Conditions||bone density, arthroplasty, replacement, hip|
|Sponsor||Yokohama City University Medical Center|
|Start date||January 2006|
|End date||April 2008|
|Trial size||60 participants|
|Trial identifier||NCT01020253, YCU07-122|
The purpose of this study is to evaluate whether alendronate and alfacalcidol are effective on prosthetic or lumbar spine BMD after total hip arthroplasty.
|Endpoint classification||efficacy study|
|Intervention model||parallel assignment|
|Masking||single blind (subject)|
DEXA QDR 2000, Hologic Co.
time frame: 1, 12, 24 and 48 weeks after operation
Male or female participants from 44 years up to 82 years old.
Inclusion Criteria: - osteoarthritis of the hip - patients after total hip arthroplasty Exclusion Criteria: - diseases related to bone metabolism - patients taking drugs which affect bone metabolism
|Official title||A Comparison of Alendronate vs. Alfacalcidol Medication for the Preservation of Bone Mineral Density Around the Femoral Implant and in the Lumbar Spine After a Total Hip Arthroplasty|
Call for more information